Novo Nordisk's head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
Novo Nordisk's head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance basliginda one cikan gelisme: Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.